BIOMAT Database Logo BIOMAT Database Logo

[Treatment of amyotrophic lateral sclerosis with TRH]. 1988

A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
Klinika Neurologii AM w Lodzi.

In view of earlier reports in the literature it was tried to use TRH (thyrotropin releasing hormone) in cases of amyotrophic lateral sclerosis. TRH was given during 3 weeks once daily intravenously in drip infusions in a 0.4 mg dose. For objectivization of the results the muscle power was assessed using a five-grade scale of Lovette. TRH effect on EMG was analysed also. It was found that in only 3 out of 14 patients with moderately progressed disease no improvement was achieved, while in 11 cases the improvement was from 10 to 20%. However, the improvement was transient, and TRH treatment failed to stop the progression of the disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009129 Muscle Tonus The state of activity or tension of a muscle beyond that related to its physical properties, that is, its active resistance to stretch. In skeletal muscle, tonus is dependent upon efferent innervation. (Stedman, 25th ed) Muscle Tension,Muscle Tightness,Muscular Tension,Tension, Muscle,Tension, Muscular,Tightness, Muscle,Tonus, Muscle
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000690 Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) ALS - Amyotrophic Lateral Sclerosis,Lou Gehrig Disease,Motor Neuron Disease, Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis With Dementia,Amyotrophic Lateral Sclerosis, Guam Form,Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam,Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1,Charcot Disease,Dementia With Amyotrophic Lateral Sclerosis,Gehrig's Disease,Guam Disease,Guam Form of Amyotrophic Lateral Sclerosis,Lou Gehrig's Disease,Lou-Gehrigs Disease,ALS Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1,Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam,Disease, Guam,Disease, Lou-Gehrigs,Gehrig Disease,Gehrigs Disease,Sclerosis, Amyotrophic Lateral

Related Publications

A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
TRH and amyotrophic lateral sclerosis.
January 1987, Neurology,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
Treatment of amyotrophic lateral sclerosis with thyrotropin-releasing hormone (TRH).
June 1986, The Japanese journal of psychiatry and neurology,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417.
April 1987, Neurology,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
[Preliminary clinical study on the treatment of amyotrophic lateral sclerosis with TRH].
December 1986, La Clinica terapeutica,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
[Treatment of amyotrophic lateral sclerosis with daily intrathecal TRH. A year's experience. Pilot study II].
January 1992, Neurologia (Barcelona, Spain),
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
[Note on the use of TRH in amyotrophic lateral sclerosis].
October 1985, Bulletin de l'Academie nationale de medecine,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
Treatment of amyotrophic lateral sclerosis.
March 1999, Drugs & aging,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
[Treatment of amyotrophic lateral sclerosis].
January 1983, Duodecim; laaketieteellinen aikakauskirja,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
[Treatment of amyotrophic lateral sclerosis].
May 1989, La Revue du praticien,
A Klimek, and J Szulc-Kuberska, and I Czernielewska-Rutkowska, and A Głuszcz-Zielińska
Treatment of amyotrophic lateral sclerosis.
July 1969, JAMA,
Copied contents to your clipboard!